在患有高级非小细胞肺癌的患者中,现实世界的维持治疗模式
Manasee V Shah1, Caitlyn T Solem1, Kelly F Bell1
1GSK, Collegeville, PA, USA.
Advances in therapy
|April 15, 2025
概括
晚期/转移性非小细胞肺癌 (a/mNSCLC) 的第一线维持治疗 (1LMT) 改善了无进展的生存率,并维持了整体生存率. 在免疫瘤学 (IO) 中添加pemetrexed并没有改善结果,并且在非状组织学中增加了不良事件.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 药理学 药理学是指药理学的学科.
背景情况:
- 包括免疫瘤学 (IO) 药物和pemetrexed在内的第一线维持治疗 (LMT) 选择已被批准用于晚期/转移性非小细胞肺癌 (a/mNSCLC).
- 对a/mNSCLC缺乏可向突变的患者的治疗模式和结果的现实数据对于优化治疗至关重要.
研究的目的:
- 评估接受1LMT的a/mNSCLC患者的现实世界治疗模式和结果.
- 为了比较不同1LMT策略的疗效和安全性,包括将pemetrexed添加到IO.
主要方法:
- 对a/mNSCLC.mNSCLC.mNSCLC.mNSCLC.mNSCLC.mNSCLC.mNSCLC.mNSCLC.mNSCLC.mNSCLC.mNSCLC.mNSCLC.mNSCLC.
- 倾向性评分权重被用来比较接受1LMT和不接受1LMT的患者之间的结果.
- 在非状/混合组织学患者中,对含有IO的1LMT添加pemetrexed的具体分析.
主要成果:
- 与没有1LMT相比,1LMT与明显更长的无进展生存 (PFS) (17.7 vs 7.1个月) 和相似的整体生存 (OS) (31.7 vs 31.0个月) 相关.
- 在非状/混合组织学中,仅接受IO的患者比接受IO加pemetrexed的患者更长时间停止治疗,PFS和OS.
- 接受IO加Pemetrexed的患者经历了更高的疲劳和贫血率.
结论:
- 第一线维护治疗 (1LMT) 改善PFS,在a/mNSCLC中维持OS,而不会显著增加医疗保健资源利用率.
- 在非状组织学/混合组织学中,添加pemetrexed与IO添加到1LMT并没有提供额外的临床益处,并且与更多不良事件有关.
- 需要新的1LMT选择来进一步提高a/mNSCLC的临床结果.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Asthma-IV: Nursing Management
2.9K
The nursing management of asthma is a comprehensive approach that relies heavily on the expertise and dedication of healthcare professionals. It involves thorough assessment, accurate diagnosis, strategic planning, effective implementation, and diligent evaluation. By meticulously following this step-by-step process, healthcare professionals play a crucial role in providing the best possible care and treatment for patients with asthma, enhancing their overall health and well-being.
First, in...
First, in...
2.9K
Pulmonary Tuberculosis V
159
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
159
Chronic Obstructive Pulmonary Disease-V: Nursing Management
3.5K
Nursing management of Chronic Obstructive Pulmonary Disease (COPD) is crucial for providing thorough care and support to patients. Nurses play an integral role in this process through detailed assessment, careful planning, targeted interventions, and ongoing evaluation. Here's an overview of the critical steps in nursing management for COPD.
Assessment
Assessment
3.5K
Cancer Survival Analysis
313
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
313


